Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...
Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...
Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback